William P. Forbes, the Chief Development Officer at Heron Therapeutics, Inc., has reported several transactions involving the company's common stock and restricted stock units. This activity, disclosed in a recent SEC filing, is significant as it reflects the executive's confidence in the company's future and its strategic direction.

Background

Heron Therapeutics, Inc. is a company focused on developing innovative pharmaceutical preparations. The company is listed under the SIC code for Pharmaceutical Preparations. Forbes, who serves as the Executive Vice President and Chief Development Officer, has been actively involved in managing his stock ownership in the company.

What the Filing Says

The filing, dated November 3, 2026, details multiple transactions by Forbes on October 30 and 31, 2026. Notably, he acquired 11,770 shares of common stock and 3,349 shares at a price of $0.28 each. Additionally, he reported acquiring restricted stock units, with 11,770 units on October 30 and 11,695 units on October 31, which vest in a staggered manner over time.

Impact

This update may affect shareholders and potential investors in Heron Therapeutics, as it showcases the level of executive confidence in the company’s growth and strategic initiatives. The pharmaceutical preparations industry may also observe increased attention as executives like Forbes actively manage their stock holdings.

What's Next

The filing does not say what happens next.